EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states


, : Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states. Journal of Clinical Endocrinology and Metabolism 64(3): 508-512

The cause of the amenorrhea that occurs in patients with hyperprolactinemia is unknown. The involvement of endogenous opioid peptides in the inhibition of GnRH release as a central factor leading to the hypogonadotropic state has been recently described. This study analyzed the LH response to opiate receptor blockade by naloxone (4 mg, iv) in groups of subjects with amenorrhea due to hyperprolactinemia of different etiologies. Patients presenting with a PRL-secreting pituitary adenoma (n = 7), idiopathic hyperprolactinemia (n = 9), or hyperprolactinemia during pharmacological treatment for schizophrenia (n = 5) were studied. Furthermore, to evaluate whether high circulating PRL levels influence the activity of the opioid system after the menopause, a group of seven postmenopausal subjects was tested before and 1 week after the administration of metoclopramide (10 mg, three times a day), a dopamine receptor antagonist. Normal premenopausal women (n = 6) served as controls. Naloxone significantly increased plasma LH levels in both prolactinoma and idiopathic hyperprolactinemic patients (P less than 0.01 vs. basal and placebo). In neither of those groups was a significant correlation found between the plasma LH response to naloxone and basal plasma PRL levels. In contrast to pathological hyperprolactinemia, blockade of opiate receptors did not significantly change LH secretion in either amenorrheic women with pharmacologically induced hyperprolactinemia or postmenopausal women. These results suggest that the effect of hyperprolactinemia on opioid modulation of LH secretion is related to the nature of the hyperprolactinemic state, supporting the existence of increased opioid inhibition of LH levels in pathological hyperprolactinemia.


Accession: 005151444

PMID: 2880862

DOI: 10.1210/jcem-64-3-508

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Quigley, M.E.; Sheehan, K.L.; Casper, R.F.; Yen, S.S., 1980: Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microadenoma. The inhibiting role of endogenous opioid peptides on gonadotropin secretion was evaluated by the infusion of an opioid receptor antagonist, naloxone (1.6 mg/h for 4 h), in 10 hyperprolactinemic patients with pituitary microadenoma (prolactinoma) a...

Evans, W.S.; Rogol, A.D.; MacLeod, R.M.; Thorner, M.O., 1980: Dopaminergic mechanisms and luteinizing hormone secretion. I. Acute administration of the dopamine agonist bromocriptine does not inhibit luteinizing hormone release in hyperprolactinemic women. The concept that dopaminergic mechanisms control LH [luteinizing hormone] secretion by modulation of gonadotropin-releasing hormone (GnRH) was recently investigated in man. Since hyperprolactinemia is associated with increased hypothalamic dopamin...

Genazzani, A.R.; Petraglia, F., 1989: Opioid control of luteinizing hormone secretion in humans. The observation that heroin-addicted subjects are amenorrheic and/or hypogonadic suggested a possible role of endogenous opioid peptides (EOP) in the regulation of the hypothala-mus-pituitary-gonodal axis. Because EOP are localized all through the...

Lafuente, A.; Marco, J.; Esquifino, A., 1996: Effects of luteinizing hormone-releasing hormone on pulsatile prolactin secretion in adult hyperprolactinemic female rats. Regulation of prolactin secretion involves complex interactions of multiple inhibitory and stimulatory factors. Among them, luteinizing hormone-releasing hormone (LHRH) has been shown, when analyzed in single samples, to exert both stimulatory and...

Foresta, C.; Indino, M.; Federspil, G.; Scandellari, C., 1985: Dopamine is not involved in the opioid control of luteinizing hormone secretion in man. The aim of this study was to examine the role of the central dopaminergic system in the mechanisms by which opioid peptides exert their influence on luteinizing hormone (LH) secretion in man. The effects of sulpiride and naloxone on the changes in...

Kalra S.P.; Leadem C.A., 1984: Control of luteinizing hormone secretion by endogenous opioid peptides. Delitala, G , M Motta And M Serio (Ed ) Frontiers in Neuroscience: Opioid Modulation Of Endocrine Function; Symposium, Florence, Italy, Oct 3-5, 1983 Xiv+282p Raven Press: New York, N Y , Usa Illus 171-184

Seki, K.; Kato, K.; Shima, K., 1986: Parallelism in the luteinizing hormone responses to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma. Endogenous opiate peptides are considered to inhibit LH secretion via a dopaminergic mechanism, and increased opioid inhibition of LH secretion has been found in some hyperprolactinemic women with a pituitary microadenoma. To assess the role of en...

Lightman, S.L.; Jacobs, H.S.; Maguire, A.K.; McGarrick, G.; Jeffcoate, S.L., 1981: Constancy of opioid control of luteinizing hormone in different pathophysiological states. This study assessed the effect of the opiate antagonist naloxone on anterior pituitary hormone release in normal subjects and patients with disturbances of the gonadotropic axis. Intravenous bolus injections of naloxone resulted in a rise of plasm...

Petraglia, F.; D'Ambrogio, G.; Comitini, G.; Facchinetti, F.; Volpe, A.; Genazzani, A.R., 1985: Impairment of opioid control of luteinizing hormone secretion in menstrual disorders. With the aim of examining central opioid influences on the control of luteinizing hormone (LH) secretion, we evaluated the LH response to naloxone, an opioid receptor antagonist, in patients affected by normo-, hyper-, and hypogonadotropic amenorr...

Petraglia, F.; Golinelli, S.; d'Ambrogio, G.; Comitini, G.; Facchinetti, F.; Volpe, A.; Genazzani, A.R., 1987: Opioid control of luteinizing hormone secretion in patients with hirsutism and hyperandrogenemia. The present study was designed to evaluate the influence of hyperandrogenemia on the activity of the opioid system regulating LH secretion in menstruating women. Ten subjects presenting with hirsutism and hyperandrogenemia and 9 healthy normally c...